Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KNSA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -129.32 Med: -3.86 Max: 579.58
Current: 54.39
During the past 10 years, the highest EV-to-EBIT of Kiniksa Pharmaceuticals International was 579.58. The lowest was -129.32. And the median was -3.86.
KNSA's EV-to-EBIT is ranked worse than 87.06% of 688
companies
in the Drug Manufacturers industry
Industry Median: 15.55
vs KNSA: 54.39
Kiniksa Pharmaceuticals International (NAS:KNSA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kiniksa Pharmaceuticals International's Enterprise Value for the quarter that ended in Jun. 2026 was $4,469.8 Mil.
Kiniksa Pharmaceuticals International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $100.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International EV-to-EBIT Related Terms
Kiniksa Pharmaceuticals International EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's EV-to-EBIT falls into.
Kiniksa Pharmaceuticals International's current Enterprise Value is $5,452.6 Mil.
Kiniksa Pharmaceuticals International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $100.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (KNSA) has a EV-to-EBIT of 54.39 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kiniksa Pharmaceuticals International and its competitors. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #599 out of 688 companies in the Drug Manufacturers industry, placing it in the top 87.1%.
Is Kiniksa Pharmaceuticals International's EV-to-EBIT too high?
Kiniksa Pharmaceuticals International's current EV-to-EBIT is 54.39. The Drug Manufacturers industry median EV-to-EBIT is 15.55. Kiniksa Pharmaceuticals International's value of 54.39 is 249.8% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #599 out of 688 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's EV-to-EBIT compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #599 out of 688 companies for EV-to-EBIT. This places Kiniksa Pharmaceuticals International in the lower half of its industry. The industry median EV-to-EBIT is 15.55. Kiniksa Pharmaceuticals International's value of 54.39 is 249.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.55, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current EV-to-EBIT of 54.39 is 249.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current EV-to-EBIT is 54.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.77, compared to a current price of $76.51 — trading 42.3% above its estimated fair value. The current EV-to-EBIT is 54.39 and 249.8% above the Drug Manufacturers industry median of 15.55. Kiniksa Pharmaceuticals International's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current EV-to-EBIT is 54.39 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $76.51 is trading 42.3% above its estimated GF Value™ of $53.77.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
EV-to-EBIT: 54.39
GF Value™: $53.77 vs. price of $76.51 (42.3% above fair value)
Industry Position: 249.8% above the Drug Manufacturers median (#599 of 688)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
47GF Score
Get the complete analysis for KNSA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
